Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
4.410
0.00 (0.00%)
At close: Jun 18, 2026, 4:00 PM EDT
4.390
-0.020 (-0.45%)
After-hours: Jun 18, 2026, 5:12 PM EDT
Immuneering Employees
Immuneering had 55 employees as of March 31, 2026. The number of employees increased by 2 or 3.77% since the number was last reported on December 31, 2025.
Employees
55
Change
2
Growth
3.77%
Revenue / Employee
n/a
Profits / Employee
-$989,812
Market Cap
285.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 55 | 2 | 3.77% |
| Dec 31, 2025 | 53 | -13 | -19.70% |
| Dec 31, 2024 | 66 | -2 | -2.94% |
| Dec 31, 2023 | 68 | -5 | -6.85% |
| Dec 31, 2022 | 73 | 9 | 14.06% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bicycle Therapeutics | 288 |
| Nautilus Biotechnology | 127 |
| Invivyd | 122 |
| Niagen Bioscience | 117 |
| Zentalis Pharmaceuticals | 106 |
| SAB Biotherapeutics | 86 |
| Cartesian Therapeutics | 75 |
| Armata Pharmaceuticals | 61 |
IMRX News
- 3 days ago - Immuneering appoints Andrew Gengos as CFO - TheFly
- 3 days ago - Immuneering Appoints Andrew Gengos as Chief Financial Officer - GlobeNewsWire
- 7 days ago - Immuneering Transcript: AGM 2026 - Transcripts
- 7 days ago - Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - GlobeNewsWire
- 17 days ago - Immuneering announces updated clinical data from atebimetinib combination trial - TheFly
- 17 days ago - Immuneering Transcript: Study result - Transcripts
- 17 days ago - Immuneering Press release: Study result - Filings
- 17 days ago - Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO - GlobeNewsWire